TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12428688

Group type: EXPERIMENTAL
Intervention: Misoprostol 600 microg four times a day (QID)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Misoprostol
Number of subjects: 6
Study: 9537487

Group type: EXPERIMENTAL
Intervention: Mixed injection of DTaP and candidate Hib vaccine
Number of subjects: 822

Group type: EXPERIMENTAL
Intervention: Separate injection of DTaP and commercial Hib vaccine
Number of subjects: 822

Group type: EXPERIMENTAL
Intervention: Separate injection of DTaP and candidate Hib vaccine
Number of subjects: 822

Group type: EXPERIMENTAL
Intervention: Booster doses (separate or mixed injections of Hib and DTaP vaccines)
Number of subjects: 822

Group type: COMPARATOR
Intervention: Mixed DTaP and Hib vaccines
Number of subjects: 822
Study: 7702021

Group type: EXPERIMENTAL
Intervention: High-resistant starch (RS) diet (59.1 +/‐ 4.7 g RS)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Low-resistant starch (RS) diet (5.2 +/‐ 0.4 g RS)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: High-resistant starch (RS) diet
Number of subjects: 8
Study: 30142047

Group type: EXPERIMENTAL
Intervention: Simulated lab instruction (E‐to‐S)
Number of subjects: 515

Group type: EXPERIMENTAL
Intervention: Standard lab instruction (S‐to‐E)
Number of subjects: 515

Group type: COMPARATOR
Intervention: Control group (standard lab instruction only)
Number of subjects: 515
Study: 28891423

Group type: EXPERIMENTAL
Intervention: Nivolumab (3 mg/kg every 2 weeks)
Number of subjects: 906

Group type: COMPARATOR
Intervention: Ipilimumab (10 mg/kg every 3 weeks for four doses, then every 12 weeks)
Number of subjects: 906

Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 906

Group type: COMPARATOR
Intervention: Ipilimumab
Number of subjects: 906
Study: 25919526

Group type: EXPERIMENTAL
Intervention: Retrievable inferior vena cava filter plus anticoagulation
Number of subjects: 399

Group type: COMPARATOR
Intervention: Anticoagulation alone
Number of subjects: 399
Study: 23178794

Group type: EXPERIMENTAL
Intervention: Steroid treatment
Number of subjects: 30

Group type: COMPARATOR
Intervention: Untreated NP
Number of subjects: 30
Study: 21530948

Group type: EXPERIMENTAL
Intervention: Robotic-assisted surgery
Number of subjects: 56

Group type: COMPARATOR
Intervention: Laparoscopic surgery
Number of subjects: 56
Study: 19433702

Group type: EXPERIMENTAL
Intervention: Intervention by ward-based pharmacists
Number of subjects: 400

Group type: COMPARATOR
Intervention: Standard care without pharmacist involvement
Number of subjects: 400
Study: 17709073

Group type: EXPERIMENTAL
Intervention: EDTA
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: EDTA + NaOCl
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: EDTAC
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: EDTAC + NaOCl
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: EGTA
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Tetracycline-HCl
Number of subjects: 60

Group type: COMPARATOR
Intervention: Distilled water
Number of subjects: 60
Study: 15017192

Group type: EXPERIMENTAL
Intervention: Computer model for predicting stone passage and duration
Number of subjects: 301

Group type: COMPARATOR
Intervention: Experienced urologists
Number of subjects: 301

Group type: COMPARATOR
Intervention: Urology residents
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Computer model tested at a private hospital
Number of subjects: 301
Study: 11696113

Group type: EXPERIMENTAL
Intervention: Liquid nutrient test meal (1350 kJ)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Mixed liquid/solid nutrient test meal (1350 kJ)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Mixed viscous/solid nutrient test meal (1350 kJ)
Number of subjects: 28
Study: 9950098

Group type: EXPERIMENTAL
Intervention: recombinant human interferon alpha 2a (rIFN alpha) at 1.0 IU/lb
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: recombinant human interferon alpha 2a (rIFN alpha) at 1.0 IU/lb and 10.0 IU/lb
Number of subjects: 177

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 177
Study: 7799590

Group type: EXPERIMENTAL
Intervention: Surgical treatment for bile duct fistula
Number of subjects: 208
Study: 3259889

Group type: EXPERIMENTAL
Intervention: Continuous infusion of propofol supplemented with nitrous oxide in oxygen (group I)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Isoflurane and nitrous oxide in oxygen (group II)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Continuous infusion of propofol with repeated bolus doses of alfentanil (group III)
Number of subjects: 60
Study: 4469858

Group type: EXPERIMENTAL
Intervention: High protein diet
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: High fat diet
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: High carbohydrate diet
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Standard diet
Number of subjects: 5
Study: 29914389

Group type: EXPERIMENTAL
Intervention: QoL‐AD (13 Items)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: QoL‐AD NH (15 Items)
Number of subjects: 73
Study: 28716357

Group type: EXPERIMENTAL
Intervention: 1000mg omega-3 fatty acids from flaxseed oil supplements, twice a day for 12 weeks
Number of subjects: 60
Study: 25438720

Group type: EXPERIMENTAL
Intervention: Autoinjector
Number of subjects: 156

Group type: COMPARATOR
Intervention: Needle and syringe
Number of subjects: 156
Study: 24187866

Group type: EXPERIMENTAL
Intervention: Massage therapy
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Ear acupuncture
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 120
Study: 21951567

Group type: EXPERIMENTAL
Intervention: Ranibizumab treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 0
Study: 18504324

Group type: EXPERIMENTAL
Intervention: Increased creatinine
Number of subjects: 10881

Group type: EXPERIMENTAL
Intervention: Decreased GFR from Cockroft and Gault
Number of subjects: 10881

Group type: EXPERIMENTAL
Intervention: Decreased GFR from Modification of Diet in Renal Disease study group
Number of subjects: 10881

Group type: EXPERIMENTAL
Intervention: Microalbuminuria
Number of subjects: 10881

Group type: EXPERIMENTAL
Intervention: Interaction between microalbuminuria and GFR from Cockroft and Gault
Number of subjects: 10881
Study: 16607544

Group type: EXPERIMENTAL
Intervention: Radioiodine therapy without carbimazole
Number of subjects: 227
Study: 14679407

Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol adjustable dosing
Number of subjects: 995

Group type: COMPARATOR
Intervention: Budesonide/formoterol fixed dosing
Number of subjects: 995
Study: 11006427

Group type: COMPARATOR
Intervention: Intervention (training to recognize metabolic hunger)
Number of subjects: 209
Study: 9206240

Group type: EXPERIMENTAL
Intervention: Hehuantang (HT)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control group (CG) - Nifedipine tablet
Number of subjects: 59
Study: 1594977

Group type: EXPERIMENTAL
Intervention: Sheehan Disability Scale
Number of subjects: 0
Study: 6692650

Group type: EXPERIMENTAL
Intervention: 12 h fast
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 48 h fast
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Lower body subatmospheric pressure after 48 h fast
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Standing after 48 h fast
Number of subjects: 9
Study: 31296133

Group type: EXPERIMENTAL
Intervention: C‐3D
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: GF‐3D
Number of subjects: 15

Group type: COMPARATOR
Intervention: HD‐2D
Number of subjects: 15
Study: 29847190

Group type: EXPERIMENTAL
Intervention: Motivational interviewing (five group sessions about hookah smoking withdrawal)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Conventional recommendations for quitting hookah (control group)
Number of subjects: 140
Study: 26890759

Group type: EXPERIMENTAL
Intervention: LC-n3-FA (2,200 mg/day, n=22)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo (n=22)
Number of subjects: 44
Study: 25442725

Group type: EXPERIMENTAL
Intervention: 1000 mg acetaminophen/10 mg hydrocodone
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 22318394

Group type: EXPERIMENTAL
Intervention: Multimeric‐001 vaccine (250 μg with adjuvant)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Multimeric‐001 vaccine (500 μg with adjuvant)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Multimeric‐001 vaccine (250 μg without adjuvant)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Multimeric‐001 vaccine (500 μg without adjuvant)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 21265202

Group type: EXPERIMENTAL
Intervention: Interferential electrical stimulation (IES)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Drug treatment (Control)
Number of subjects: 166
Study: 17492298

Group type: EXPERIMENTAL
Intervention: New technique for sacrospinous ligament fixation
Number of subjects: 57

Group type: COMPARATOR
Intervention: Deschamps ligature carrier
Number of subjects: 57
Study: 14985677

Group type: EXPERIMENTAL
Intervention: Biochanin (40 mg/day)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80

Group type: COMPARATOR
Intervention: Biochanin vs Placebo
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Formononetin
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo for Formononetin
Number of subjects: 80
Study: 11824703

Group type: EXPERIMENTAL
Intervention: Reading the piece of fiction
Number of subjects: 85

Group type: COMPARATOR
Intervention: Listening to the piece of fiction
Number of subjects: 85

Group type: COMPARATOR
Intervention: Watching the piece of fiction
Number of subjects: 85
Study: 9715673

Group type: EXPERIMENTAL
Intervention: NFPA 1500 (1987) standard configuration
Number of subjects: 10

Group type: COMPARATOR
Intervention: Hip-boot configuration
Number of subjects: 10
Study: 7519977

Group type: EXPERIMENTAL
Intervention: Buprenorphine 12 mg/day
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Buprenorphine (2 mg/day and 6 mg/day)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo buprenorphine
Number of subjects: 6
Study: 2500941

Group type: EXPERIMENTAL
Intervention: High doses of insulin in class B-F diabetic patients
Number of subjects: 112

Group type: COMPARATOR
Intervention: Diet
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Corticosteroids administration to the mother
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Phosphatidylglycerol determination in amniotic fluid
Number of subjects: 112
Study: 31648515

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided transversus abdominis plane (TAP) block using 0.25% bupivacaine solution (0.5 ml kg−1)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided quadratus lumborum (QL) block using 0.25% bupivacaine solution (0.5 ml kg−1)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Caudal epidural block using 0.25% bupivacaine solution (0.5 ml kg−1)
Number of subjects: 94
Study: 29155036

Group type: EXPERIMENTAL
Intervention: App-based self-acupressure
Number of subjects: 221

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 221
Study: 27439031

Group type: EXPERIMENTAL
Intervention: Montelukast (4 or 5 mg daily for 16 weeks)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 24580721

Group type: EXPERIMENTAL
Intervention: Headstrong CD-ROM program
Number of subjects: 35

Group type: COMPARATOR
Intervention: Educational control CD-ROM program
Number of subjects: 35
Study: 22735866

Group type: EXPERIMENTAL
Intervention: Metoprolol IV 5‐15 mg or up to HR ≤ 60 bpm (M)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Diltiazem IV 0.25 to 0.60 mg/kg or up to HR ≤ 60 bpm (D)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 50
Study: 19687327

Group type: EXPERIMENTAL
Intervention: Gemcitabine-based chemotherapy
Number of subjects: 55

Group type: COMPARATOR
Intervention: Proteolytic enzyme therapy
Number of subjects: 55
Study: 17653691

Group type: EXPERIMENTAL
Intervention: Micronised fenofibrate (200 mg/day)
Number of subjects: 171
Study: 15774493

Group type: EXPERIMENTAL
Intervention: Resting heart rate > or =83 bpm
Number of subjects: 24913

Group type: EXPERIMENTAL
Intervention: Resting heart rate between 77-82 bpm
Number of subjects: 24913

Group type: COMPARATOR
Intervention: Resting heart rate < or =62 bpm
Number of subjects: 24913
Study: 12474116

Group type: EXPERIMENTAL
Intervention: Tandospirone (60 mg)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Tandospirone (30 mg or 60 mg)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 10405985

Group type: EXPERIMENTAL
Intervention: Moderate aerobic exercise training (EXC)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Flexibility/toning control (FT-CON)
Number of subjects: 29
Study: 7588663

Group type: EXPERIMENTAL
Intervention: Propofol 2.5 mg kg‐1
Number of subjects: 38

Group type: COMPARATOR
Intervention: Thiopentone 4.0 mg kg‐1
Number of subjects: 38
Study: 2123904

Group type: EXPERIMENTAL
Intervention: Thrombolytic agent (100 mg of recombinant tissue‐type plasminogen activator given over 3 h)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study: 7012968

Group type: EXPERIMENTAL
Intervention: Intermittent tetracycline therapy
Number of subjects: 2

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 2
Study: 31944884

Group type: EXPERIMENTAL
Intervention: Titanium nitride (TIN) Gracey curette
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Er:YAG laser (Er:YAG tip) chisel
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ultrasonic piezoelectric device with a special tip designed for root surfaces (H3)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Stainless steel (SS) Gracey curette
Number of subjects: 20
Study: 30632208

Group type: EXPERIMENTAL
Intervention: Dornase alfa (2.5 ml, nebulized once daily for 1 month)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control (5 ml of isotonic saline, nebulized once daily for 1 month)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Dornase alfa
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control (isotonic saline)
Number of subjects: 32
Study: 28291691

Group type: EXPERIMENTAL
Intervention: Structured educational intervention applied to experimental group once a month for three months.
Number of subjects: 103
Study: 26390397

Group type: EXPERIMENTAL
Intervention: Treadmill walking under single task (walk only) condition
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Treadmill walking under dual task (walk performing a simultaneous cognitive task) condition
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Cognitive performance during treadmill walking
Number of subjects: 38

Group type: COMPARATOR
Intervention: Overground walking under single task condition
Number of subjects: 38

Group type: COMPARATOR
Intervention: Overground walking under dual task condition
Number of subjects: 38
Study: 24290960

Group type: EXPERIMENTAL
Intervention: Plasma c‐proteasome activity measured at 12‐16 h after injury
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Plasma c‐proteasome activity
Number of subjects: 50
Study: 22658931

Group type: EXPERIMENTAL
Intervention: Anthrax Vaccine Adsorbed (AVA)
Number of subjects: 726
Study: 19172441

Group type: EXPERIMENTAL
Intervention: Manual fundal pressure during the second stage of labor
Number of subjects: 197

Group type: COMPARATOR
Intervention: No manual fundal pressure during the second stage of labor
Number of subjects: 197
Study: 17222288

Group type: EXPERIMENTAL
Intervention: De‐nicotinized cigarettes
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Nicotine‐containing cigarettes
Number of subjects: 30

Group type: COMPARATOR
Intervention: No smoking
Number of subjects: 30
Study: 15177816

Group type: EXPERIMENTAL
Intervention: Phonological awareness, morphological/syntactic skill, and naming speed
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Naming speed
Number of subjects: 199
Study: 11988933

Group type: EXPERIMENTAL
Intervention: Type I collagen (filled defects)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Type I collagen (filled defects in patients)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (unfilled defects in rabbits)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (unfilled cavities in patients)
Number of subjects: 16
Study: 9579258

Group type: EXPERIMENTAL
Intervention: Intravenous tenoxicam (20 mg) administered 30 min before surgery
Number of subjects: 77

Group type: COMPARATOR
Intervention: Intravenous tenoxicam (20 mg) administered after incision
Number of subjects: 77
Study: 7622092

Group type: EXPERIMENTAL
Intervention: Recruitment strategies (press releases and newspaper advertisements)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Declined participants
Number of subjects: 0
Study: 2793304

Group type: EXPERIMENTAL
Intervention: Cambridge Diet (CD)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Milk diet
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Change from CD to Milk
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Jaw wiring (during outpatient phase)
Number of subjects: 17
Study: 6108726

Group type: EXPERIMENTAL
Intervention: KWD 2131
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 30926451

Group type: EXPERIMENTAL
Intervention: Self-learning training
Number of subjects: 1301

Group type: COMPARATOR
Intervention: Instructor-led training
Number of subjects: 1301
Study: 28219610

Group type: EXPERIMENTAL
Intervention: Bictegravir plus emtricitabine and tenofovir alafenamide
Number of subjects: 98

Group type: COMPARATOR
Intervention: Dolutegravir plus emtricitabine and tenofovir alafenamide
Number of subjects: 98
Study: 25845544

Group type: EXPERIMENTAL
Intervention: Next generation KA01 chitosan wound dressing
Number of subjects: 90

Group type: COMPARATOR
Intervention: Traditional vaseline gauze
Number of subjects: 90
Study: 23289969

Group type: EXPERIMENTAL
Intervention: Amlodipine (5-10 mg/day)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Valsartan (80-320 mg/day)
Number of subjects: 46
Study: 19341012

Group type: EXPERIMENTAL
Intervention: Individually tailored psychosocial intervention
Number of subjects: 28

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 28
Study: 15468367

Group type: EXPERIMENTAL
Intervention: Topical diclofenac solution (50 drops applied 3 times daily for 12 weeks)
Number of subjects: 622

Group type: COMPARATOR
Intervention: Oral diclofenac (50 mg capsules taken 3 times daily for 12 weeks)
Number of subjects: 622
Study: 11020769

Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid drainage during surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard surgical procedure without cerebrospinal fluid drainage
Number of subjects: 0
Study: 8642490

Group type: EXPERIMENTAL
Intervention: Wheat/soy cereals with 8.0% dietary fiber (DF)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Wheat/soy cereals with 1.8% dietary fiber (DF)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Wheat/milk cereals
Number of subjects: 57
Study: 1557274

Group type: EXPERIMENTAL
Intervention: Capitation payments with financial risk-sharing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Visit fees set at twice regular Medicaid fees
Number of subjects: 0

Group type: COMPARATOR
Intervention: Regular Medicaid program (fee-for-service, low fees)
Number of subjects: 0
Study: 3926613

Group type: EXPERIMENTAL
Intervention: 120 mg isosorbide dinitrate (ISDN) in sustained-release form (SR)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 120 mg ISDN SR with 100 mg atenolol
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 120 mg ISDN SR, 100 mg atenolol and 20 mg nifedipine in sustained release form
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 31669615

Group type: EXPERIMENTAL
Intervention: Endplate defects
Number of subjects: 478

Group type: EXPERIMENTAL
Intervention: Focal and erosive endplate defects
Number of subjects: 478

Group type: EXPERIMENTAL
Intervention: All three types of endplate defects
Number of subjects: 478
Study: 30062603

Group type: EXPERIMENTAL
Intervention: Sexually assertive behavior in women (Study 1a and 1b)
Number of subjects: 1031

Group type: COMPARATOR
Intervention: Sexually timid behavior in women (Study 1a and 1b)
Number of subjects: 1031

Group type: EXPERIMENTAL
Intervention: Sexually assertive behavior in men (Study 2)
Number of subjects: 1031

Group type: COMPARATOR
Intervention: Sexually timid behavior in men (Study 2)
Number of subjects: 1031
Study: 28813512

Group type: EXPERIMENTAL
Intervention: Standard intervention package of cardiovascular disease care including prescription of a standardized package of medicines, lifestyle intervention advice, and medication adherence advice; implemented over 12 months.
Number of subjects: 28130

Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 28130

Group type: EXPERIMENTAL
Intervention: Standard intervention package of cardiovascular disease care.
Number of subjects: 28130
Study: 25332150

Group type: EXPERIMENTAL
Intervention: Catheter ablation
Number of subjects: 27

Group type: COMPARATOR
Intervention: Antiarrhythmic medication
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 27
Study: 23458201

Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 supplementation
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 21131688

Group type: EXPERIMENTAL
Intervention: Silicone ring tourniquet (Hemaclear®)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Pneumatic tourniquet
Number of subjects: 20
Study: 19799201

Group type: EXPERIMENTAL
Intervention: Low-protein diet (LPD) with essential keto/amino acids (0.6 g/kg/day) for 24-48 months
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Low-protein diet (LPD) with highly purified soya protein (0.3 g/kg/day) in a highly energetic nutrient mixture for 24-48 months
Number of subjects: 46

Group type: COMPARATOR
Intervention: Free diet
Number of subjects: 46
Study: 16473754

Group type: EXPERIMENTAL
Intervention: Real moxibustion
Number of subjects: 71

Group type: COMPARATOR
Intervention: Sham moxibustion
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Practitioner assessment of treatment (Real moxibustion)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Practitioner assessment of treatment (Sham moxibustion)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Practitioner assessment of treatment (Undisclosed treatment)
Number of subjects: 71